AU2003292045A1 - Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases - Google Patents

Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases

Info

Publication number
AU2003292045A1
AU2003292045A1 AU2003292045A AU2003292045A AU2003292045A1 AU 2003292045 A1 AU2003292045 A1 AU 2003292045A1 AU 2003292045 A AU2003292045 A AU 2003292045A AU 2003292045 A AU2003292045 A AU 2003292045A AU 2003292045 A1 AU2003292045 A1 AU 2003292045A1
Authority
AU
Australia
Prior art keywords
diseases
prevention
treatment
nucleic acids
acids encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003292045A
Other languages
English (en)
Other versions
AU2003292045A8 (en
Inventor
Matthias Lechmann
Alexander Steinkasserer
Elisabeth Zinser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003292045A1 publication Critical patent/AU2003292045A1/en
Publication of AU2003292045A8 publication Critical patent/AU2003292045A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
AU2003292045A 2002-11-19 2003-11-19 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases Abandoned AU2003292045A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02025851A EP1422241A1 (en) 2002-11-19 2002-11-19 Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
EP02025851.3 2002-11-19
PCT/EP2003/012941 WO2004046182A2 (en) 2002-11-19 2003-11-19 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases

Publications (2)

Publication Number Publication Date
AU2003292045A1 true AU2003292045A1 (en) 2004-06-15
AU2003292045A8 AU2003292045A8 (en) 2004-06-15

Family

ID=32187165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003292045A Abandoned AU2003292045A1 (en) 2002-11-19 2003-11-19 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases

Country Status (9)

Country Link
US (3) US7893200B2 (enExample)
EP (5) EP1422241A1 (enExample)
JP (3) JP4740595B2 (enExample)
AU (1) AU2003292045A1 (enExample)
CA (2) CA2507373C (enExample)
DK (1) DK1562985T3 (enExample)
ES (2) ES2413631T3 (enExample)
SI (1) SI1562985T1 (enExample)
WO (1) WO2004046182A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CN104177464B (zh) * 2006-08-18 2017-04-12 阿哥斯医疗公司 Cd83在联合治疗中的用途
US8513208B2 (en) 2008-02-28 2013-08-20 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
WO2009142759A1 (en) * 2008-05-23 2009-11-26 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use
EP2497498A4 (en) 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
CN104610452B (zh) * 2015-01-27 2018-11-20 中国科学技术大学先进技术研究院 抗人cd83单克隆抗体及其制备、鉴定和应用
EP3318577A4 (en) 2015-06-30 2019-01-23 Osaka University ANTIPLEXIN A1 AGONISTANTIKÖRPER
CA3042683A1 (en) 2016-11-07 2018-05-11 Coimmune, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
MX390707B (es) 2017-01-31 2025-03-21 Kimberly Clark Co Composición antibacteriana que incluye un éster del ácido benzoico y métodos de inhibición del crecimiento bacteriano mediante el uso de la misma.
EP3895723A1 (en) 2020-04-16 2021-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Scd83 for wound healing, hair growth, and skin and hair care
DE102024110866A1 (de) * 2024-04-18 2025-10-23 Christian Arnold Pharmazeutische Zusammensetzung zur Heilung einer Wunde

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
WO1997029781A1 (en) * 1996-02-15 1997-08-21 Immunex Corporation Methods and compositions for modulating an immune response
CA2301660A1 (en) 1997-08-26 1999-03-04 Zymogenetics, Inc. Adipocyte-specific protein homologs
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
GB2370273A (en) 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
EP1436319A2 (en) * 2001-10-18 2004-07-14 Zlatko Ademovic Repetitive motifs from salivary proline rich proteins, mucin and collagen
CA2466845A1 (en) 2001-11-21 2003-06-05 Fred Ramsdell Manipulation of cytokine levels using cd83 gene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US6652537B2 (en) 2001-12-12 2003-11-25 C. R. Bard, Inc. Articulating stone basket
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
WO2009142759A1 (en) 2008-05-23 2009-11-26 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use

Also Published As

Publication number Publication date
JP5878584B2 (ja) 2016-03-08
EP1562985A2 (en) 2005-08-17
AU2003292045A8 (en) 2004-06-15
HK1194400A1 (en) 2014-10-17
US20150065684A1 (en) 2015-03-05
JP2006523432A (ja) 2006-10-19
CA2847795C (en) 2018-05-01
HK1079220A1 (en) 2006-03-31
JP2014195455A (ja) 2014-10-16
EP2692733B1 (en) 2015-11-18
JP4740595B2 (ja) 2011-08-03
ES2413631T3 (es) 2013-07-17
EP1562985B1 (en) 2015-01-07
US9732140B2 (en) 2017-08-15
CA2847795A1 (en) 2004-06-03
DK1562985T3 (da) 2015-04-13
EP2345670A1 (en) 2011-07-20
US7893200B2 (en) 2011-02-22
JP2011144177A (ja) 2011-07-28
JP5557765B2 (ja) 2014-07-23
US8759505B2 (en) 2014-06-24
CA2507373A1 (en) 2004-06-03
CA2507373C (en) 2014-06-10
US20120015890A1 (en) 2012-01-19
EP3031824A1 (en) 2016-06-15
US20070167607A1 (en) 2007-07-19
WO2004046182A2 (en) 2004-06-03
EP2345670B1 (en) 2013-03-20
EP2692733A1 (en) 2014-02-05
ES2534308T3 (es) 2015-04-21
WO2004046182A3 (en) 2004-10-14
SI1562985T1 (sl) 2015-05-29
EP1422241A1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003301024A1 (en) Inflatable products and methods of their formation and use
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003216592A1 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
AU2002247004A1 (en) Methods of diagnosis and treatment of osteoporosis
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
AU2003249645A1 (en) METHODS FOR THE IDENTIFICATION OF IKKAlpha FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
AU2003292045A8 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases
AU2003299378A1 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase